This brief commentary describes the reflections on a fundamental question by the Public Interest Group on Cancer Research, a successful academic-community partnership focused on cancer research, education, public engagement, and advocacy in Canada's Eastern province of Newfoundland and Labrador. Our Group has achieved some success in a short time with very limited funding. It has successfully created public spaces for conversations about cancer care and priorities for research and regularly advocated for health service change prioritized by input from patients and family members. However, we remain challenged in our understanding of how to truly implement change within oncology care contexts that is informed by patients and families affected by cancer. In this short reflection, we hope to raise awareness of this important issue and question whose responsibility it is to work with patients and families and follow through on prioritized healthcare issues and services. We suggest this may be a matter of integrated knowledge translation and a better understanding of where patients and families fit in this space. We hope to encourage reflection and conversation among all relevant stakeholders about how best to implement patient-prioritized change in oncology care and policy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593104 | PMC |
http://dx.doi.org/10.3390/curroncol31110538 | DOI Listing |
Hepatol Commun
February 2025
Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
The global epidemiology of HCC is shifting due to changes in both established and emerging risk factors. This transformation is marked by an emerging prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, alongside traditional risks such as viral hepatitis (HBV and HCV), and exposure to chemical agents like aflatoxin, alcohol, tobacco, and air pollution. This review examines how environmental exposures and evolving liver pathology, exacerbated by lifestyle and metabolic conditions, are contributing to the rising worldwide incidence of HCC.
View Article and Find Full Text PDFRev Bras Enferm
January 2025
Universidade do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
Objectives: to analyze the social representations of patients with cancer regarding oncologic surgery.
Methods: a qualitative study based on Social Representation Theory was conducted with 126 participants between October 2021 and May 2022 in a public hospital in Rio de Janeiro. A characterization questionnaire, free evocations of the inducing term "surgery", and semi-structured interviews with 60 participants were applied.
Rev Gaucha Enferm
January 2025
Universidade Federal de São Paulo, Escola Paulista de Enfermagem, São Paulo, São Paulo, Brasil.
Objective: To analyze family dynamics, the support network of family caregivers of individuals with progressive cancer, and their needs for comprehensive care.
Method: Qualitative, descriptive study developed based on the Calgary Family Assessment Model framework. It was conducted from September 2022 to April 2023, through participant observation at a public health institution in São Paulo and interviews with six family caregivers.
PLoS One
January 2025
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Background: To study the efficacy and safety of Polyethylene glycolated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the prevention of neutropenia during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC).
Methods: This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. Participants were divided into an experimental group and a control group.
AIDS
January 2025
Pediatric Hematology and Immunology Department, Necker Hospital, GHU APHP.Centre - Université de Paris, Paris, France.
Objective: Most data published on adolescents living with HIV (ALH) have been collected before the large diffusion of second-generation integrase strand transfer inhibitors (INSTI) among the pediatric population. We analyzed the nationwide ANRS-MIE CO10 Pediatric cohort to assess the changes over time in health and social outcomes of French ALH.
Design: The cohort enrolled children born in France since 1985 and, from 2005, children diagnosed with HIV at ≤13 years, including those born abroad if antiretroviral-naive at first medical care in France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!